Skip to main content
PMC home page
Cell Death and Differentiation logoLink to Cell Death and Differentiation
. 2015 Oct 16;23(4):576–582. doi: 10.1038/cdd.2015.121

The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice

C Trierweiler 1, B Hockenjos 1, K Zatloukal 2, R Thimme 1, H E Blum 1, E F Wagner 3, P Hasselblatt 1,*
PMCID: PMC4986630  PMID: 26470729

Abstract

Hepatocellular carcinoma (HCC) develops as a consequence of chronic inflammatory liver diseases such as chronic hepatitis B virus (HBV) infection. The transcription factor c-Jun/activator protein 1 (AP-1) is strongly expressed in response to inflammatory stimuli, promotes hepatocyte survival during acute hepatitis and acts as an oncogene during chemically induced liver carcinogenesis in mice. Here, we therefore aimed to characterize the functions of c-Jun during HBV-related liver tumorigenesis. To this end, transgenic mice expressing all HBV envelope proteins (HBV+), an established model of HBV-related HCC, were crossed with knockout mice lacking c-Jun specifically in hepatocytes and tumorigenesis was analyzed. Hepatic expression of c-Jun was strongly induced at several time points during tumorigenesis in HBV+ mice, whereas expression of other AP-1 components remained unchanged. Importantly, formation of premalignant foci and tumors was strongly reduced in HBV+ mice lacking c-Jun. This phenotype correlated with impaired hepatocyte proliferation and increased expression of the cell cycle inhibitor p21, whereas hepatocyte survival was not affected. Progression and prognosis of HBV-related HCC correlates with the expression of the cytokine osteopontin (Opn), an established AP-1 target gene. Opn expression was strongly reduced in HBV+ livers and primary mouse hepatocytes lacking c-Jun, demonstrating that c-Jun regulates hepatic Opn expression in a cell-autonomous manner. These findings indicate that c-Jun has important functions during HBV-associated tumorigenesis by promoting hepatocyte proliferation as well as progression of dysplasia. Therefore, targeting c-Jun may be a useful strategy to prevent hepatitis-associated tumorigenesis.

Hepatocellular carcinoma (HCC) frequently develops as a consequence of chronic inflammatory liver diseases such as chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, chronic inflammation, liver injury, fibrosis and subsequent cirrhosis. HCC is the seventh and fifth most common cancer in women and men, respectively, and its incidence is particularly high in developing countries, in which HBV and HCV infections are endemic.1 HBV is considered to be non-cytopathic in most cases and the majority of HBV-related liver damage has been attributed to hepatic immune responses.2 However, HBV may directly promote tumorigenesis by genomic integration of viral DNA or by the action of viral transactivators such as HBx or mutant preS2 surface proteins.3 In keeping with this notion, overexpression of hepatoviral proteins in transgenic mice is sufficient to cause HCC as shown in Tg(Alb-1HBV)Bri44 mice (hereafter referred to as HBV+ mice), which express the large, middle and small isoforms of HBV surface proteins (LHBs, MHBs and HBs antigens) under the control of the albumin promoter as well as HBx from its endogenous promoter.4 Although liver disease in this model does not include viral replication, cccDNA formation and HBV-specific immune cell responses, liver disease in these animals is characterized by accumulation of hepatoviral proteins in the endoplasmic reticulum (ER) and appearance of ‘ground glass hepatocytes', liver damage with compensatory proliferation, aneuploidy, dysplasia and eventually HCC, thereby mimicking several aspects of disease pathogenesis in HBV-infected patients.5, 6, 7 HBV+ mice therefore represent a useful tool to genetically dissect molecular pathways related to hepatitis-associated hepatocarcinogenesis. HBV replication and expression of hepatoviral proteins such as HBx strongly activate c-Jun.3, 8, 9, 10 c-Jun is a member of the dimeric activator protein 1 (AP-1) transcription factor family, which mainly consists of Jun (c-Jun, JunB and JunD) and Fos proteins (c-Fos, FosB, Fra-1 and Fra-2).11 c-Jun is expressed as an immediate early gene in response to a variety of stress stimuli, growth factors and subsequent signaling through MAP kinase pathways. It is a major determinant of cell fate in the liver and regulates hepatocyte survival during acute hepatitis and ER stress8, 12 as well as hepatocyte proliferation following 2/3 partial hepatectomy.13 Moreover, c-Jun acts as an oncogene in the liver and strongly promotes liver tumorigenesis in models of chemically induced HCC.14, 15, 16 However, the functions of c-Jun during HBV-related liver disease are only poorly defined, although the above-mentioned findings strongly suggest that c-Jun may be a central regulator of HBV-mediated hepatocarcinogenesis. To address this issue experimentally, we generated HBV+ transgenic mice specifically lacking c-Jun in hepatocytes. Our findings indeed indicate that c-Jun has important functions during HBV-related tumorigenesis by regulating hepatocyte proliferation as well as progression of dysplasia.

Results

Increased expression of c-Jun in HBV + mice

To analyze the expression of c-Jun at various stages of HBV-related tumorigenesis, hepatic expression of c-Jun was determined by quantitative PCR (qPCR) in HBV+ mice. In comparison to HBV− controls, c-Jun expression was increased at all time points studied and peaked at around 6 months of age (Figure 1a, Supplementary Figure S1A). Moreover, hepatic c-Jun expression was also increased in a separate infectious mouse model of hepatitis B (Supplementary Figure S1B). In contrast, expression of JunB was not induced in HBV+ livers at 6 months of age, whereas JunD expression was slightly increased in HBV+ livers irrespective of c-Jun expression (Figure 1b). Expression of Fos genes could not be detected (Figure 1b). Immunohistochemistry of HBV+ livers revealed that c-Jun was expressed in hepatocytes and inflammatory cells (Figure 1c). Hepatic c-Jun expression was substantially reduced in HBV−c-JunΔli and HBV+ c-JunΔli livers (Figure 1b), in which residual c-Jun expression occurred in non-parenchymal cells (Figure 1c). These findings indicate that c-Jun expression is induced following HBV infection and in HBV transgenic mice. Moreover, transgene expression of small and large HBsAg at 6 months of age was analyzed by ELISA and immunoblotting, respectively, and revealed that transgene expression was not altered in the absence of c-Jun (Supplementary Figure S1C), indicating that this mouse model was indeed suitable to further study the functions of c-Jun in HBV-related tumorigenesis.

Figure 1.

Figure 1

Open in a new tab

c-Jun expression is induced in HBV+ mice. (a) Hepatic c-Jun mRNA expression at the indicated time points was determined by qPCR and normalized to the expression in HBV- livers (n≥4 per genotype and time point, significance was tested by Mann–Whitney test). (b) Hepatic expression of AP-1 family members in mice with the indicated genotypes at 6 months of age was analyzed by RNase protection assay. Gapdh expression was used as loading control. (c) c-Jun expression in livers of 6-month-old mice with the indicated genotypes as determined by immunohistochemistry. Note the expression in hepatocytes (black arrows) and inflammatory cells (red arrows)

c-Jun strongly promotes HBV-related tumorigenesis

To determine the impact of c-Jun expression on HBV-related tumorigenesis, HBV+ c-Junf/f and HBV+ c-JunΔli mice were analyzed at 12 months of age. No obvious macroscopical liver abnormalities were observed in HBV− c-Junf/f and c-JunΔli mice (Figure 2a). In contrast, liver tumors were apparent macroscopically in 15/22 HBV+ c-Junf/f mice, whereas livers appeared normal and tumor-free in all 16 HBV+ c-JunΔli mice (Figure 2a). These findings correlated with a significant increase in liver weight in HBV+ c-Junf/fi as compared with HBV+ c-JunΔli mice (Figure 2b). Moreover, tumorigenesis was also quantified microscopically and confirmed that tumorigenesis was strikingly reduced at this time point in HBV+ mice lacking c-Jun (Figure 2c). Histopathological hallmarks of HBV+ livers include the appearance of ground glass hepatocytes due to accumulation of surface proteins in the ER, inflammation, cellular atypia and the appearance of atypical foci, which progress to hyperplastic nodules, adenoma, and eventually HCC.5 Infiltration of CD3+ T cells and Ly6G+ neutrophils was not altered in HBV+ mice lacking c-Jun (Supplementary Figure S2A). The appearance of ground glass hepatocytes, inflammation and cellular atypia were comparable in HBV+ c-Junf/f and HBV+ c-JunΔli livers as determined by histopathological analysis, whereas numbers of atypical foci and subsequent pro-tumorigenic alterations were profoundly reduced in the absence of c-Jun (Figures 3a and b). c-Jun expression was observed in most HBV-related pathologies including ground glass hepatocytes, adenoma and HCC (Supplementary Figure S2B). It should be noted that most of the tumor lesions observed in HBV+ livers here were hyperplastic nodules or adenomas and that the prevalence of HCC in HBV+ c-Junf/f mice was low at the age of 12 months. However, it has been shown that the precursor lesions observed here can be used as tumor surrogate and predict hepatocarcinogenesis at later time points.7 Moreover, expression of HBsAg is gradually downregulated during neoplastic transformation and areas lacking transgene expression can therefore be used as a predictor of tumorigenesis.7 Although transgene expression was comparable at 6 months of age, immunohistochemistry revealed that HBsAg expression was lost in many liver areas of HBV+ c-Junf/f mice at 12 months of age consistent with the formation of preneoplastic foci, but rarely in HBV+ c-JunΔli mice (Supplementary Figure S1D). Tumor analysis was therefore not extended beyond 12 months. In conclusion, our findings indicate that c-Jun is an important regulator of tumorigenesis in HBV+ mice.

Figure 2.

Figure 2

Open in a new tab

Liver tumorigenesis is strongly reduced in 12-month-old HBV+ mice lacking c-Jun. (a) Macroscopical images of representative livers of mice with the indicated genotypes. Black bar=1 cm. (b) Liver weight was determined as liver/body weight ratio, (n=4–21 per genotype, significance was tested by Mann–Whitney test (MWT)). (c) Liver tumorigenesis was quantified histologically and is given as tumor numbers per cm2 liver tissue. Tumor load was determined as a ratio of tumorous tissue and non-tumorous tissue and is given in (%). Significance was tested by MWT

Figure 3.

Figure 3

Open in a new tab

Absence of atypical foci and dysplastic progression in HBV+ mice lacking c-Jun. (a) Representative histological stainings of mice with the indicated genotypes are shown (12 months of age). Note the appearance of ground glass hepatocytes in HBV+ mice, which occurred irrespective of c-Jun expression. (b) Histological alterations observed in mice with the indicated genotypes were scored using an arbitrary scale from 0 to 3

c-Jun promotes hepatocyte proliferation in HBV+ livers

c-Jun is an important regulator of hepatocyte proliferation, survival and related stress responses. We have previously shown that c-Jun expression determines hepatocyte survival during T-cell-mediated hepatitis as well as during chemically induced ER stress,8, 12 raising the question whether similar functions may be relevant in HBV+ mice. However, expression of the established ER stress marker genes BiP and Gadd153 as well as XBP-1 splicing were not significantly induced in HBV+ as compared with HBV- livers and not altered in the absence of c-Jun (Supplementary Figure S3A). To further analyze the impact of c-Jun expression on hepatocyte damage, serum transaminase concentrations were measured. Serum alanine aminotransferase (ALT) concentrations in HBV+ mice peaked at the age of 6 months and decreased thereafter, but were not altered in the absence of c-Jun (Figure 4a), suggesting that c-Jun is not involved in regulating hepatocyte damage or survival in this model. In keeping with this notion, no difference in cell death could be observed by TUNEL staining, whereas the numbers of TUNEL+ cells were very low overall (Supplementary Figure S4). Previous findings suggest that c-Jun promotes DEN-mediated and HCV-related hepatocarcinogenesis by regulating the expression of Birc5 or activation of Stat3.15, 16 In HBV+ mice, hepatic Birc5 expression was not altered in the absence of c-Jun (Supplementary Figure S3A). Although Stat3 phosphorylation was evident in HBV+ livers, its phosphorylation as well as expression of Socs3 was not changed in c-Jun-deficient livers (Supplementary Figure S3B), indicating that the Stat3 pathway does not contribute to the differences observed in HBV+ c-JunΔli mice.

Figure 4.

Figure 4

Open in a new tab

c-Jun promotes hepatocyte proliferation by interfering with p21. (a) Liver damage in mice with the indicated genotypes was determined by analysis of serum ALT concentrations at 6 and 12 months, respectively. (n=12–16 per genotype and time point). (b and c) Hepatocyte proliferation was assessed by immunohistochemistry for Ki67 at 6 and 12 months of age, respectively. For quantification, three representative high-power fields were analyzed per mouse. (n≥4 per genotype and time point; significance was tested by Mann–Whitney test). p21 expression was analyzed by immunohistochemistry

Hepatocarcinogenesis in HBV+ mice is preceded by sustained hepatocyte proliferation.17 Hepatocyte proliferation was significantly reduced in HBV+ livers lacking c-Jun at the age of 6 and 12 months (Figures 4b and c), whereas hepatic expression of the cell cycle inhibitor and tumor suppressor p21 was increased (Figure 4c; Supplementary Figure S5A). Moreover, HBV+ c-Junf/f primary mouse hepatocytes (PMH) were isolated and infected with adenoviral vectors expressing Cre recombinase, which resulted in profound inhibition of c-Jun expression, whereas p21 expression was significantly induced (Supplementary Figure S5B). These findings strongly suggest that c-Jun interferes with hepatic p21 expression in a cell-autonomous manner.

c-Jun regulates hepatic Opn expression

Our finding that progression of dysplasia was reduced in c-Jun mutant livers raises the question whether c-Jun also regulates the expression of genes related to the progression of dysplastic lesions such as osteopontin (Opn). Opn is highly expressed in HCC and correlates with histological tumor grading, tumor stage as well as early recurrence following surgical resection, in particular in HBV-infected patients.18 Importantly, hepatic Opn expression was induced in HBV+ mice at the age of 12 months as determined by qPCR, ELISA and immunoblotting, but reduced in the absence of c-Jun (Figures 5a and b; Supplementary Figure S3B). To address the question whether c-Jun promotes hepatocellular Opn expression in a cell-autonomous manner, PMH were isolated. Opn expression was indeed reduced in HBV+ c-JunΔli PMH as determined by qPCR and ELISA (Figure 5c). Opn expression was also impaired in HBV+ c-Junf/f PMH upon adenoviral transfer of Cre recombinase (Supplementary Figure S5B), indicating that this phenotype was independent of the AlfpCre transgene used here. Immunohistochemistry further revealed that Opn expression was restricted to bile duct epithelia in HBV+ c-JunΔli livers. In HBV+ c-Junf/f livers, it occurred in some dysplastic foci and scattered hepatocytes as well as in bile duct epithelia and proliferative ductular cells. These cells also expressed Sox9 and cytokeratin 19 (CK19) (Figure 5d), which also identify hepatic and liver cancer progenitor cells.19 Moreover, hepatic Opn expression was also reduced in c-JunΔli mice during acute concanavalin A (ConA)-mediated hepatitis (Supplementary Figure S5C), indicating that c-Jun regulates Opn expression also in other models of inflammatory liver disease. In conclusion, these findings indicate that c-Jun regulates hepatic Opn expression in a cell-autonomous manner, which in turn promotes HBV-related tumorigenesis.

Figure 5.

Figure 5

Open in a new tab

c-Jun regulates hepatic Opn expression. (a and b) Hepatic Opn expression was determined at the indicated time points by qPCR (a) and ELISA (b), respectively. Opn RNA expression was normalized to expression in HBV- controls. (n≥4 per genotype and time point, significance was tested by Mann–Whitney test (MWT)). (c) Opn expression in primary hepatocytes was determined by qPCR and ELISA from the supernatant, respectively. (n≥4 per genotype, significance was tested by MWT). (d) Expression analysis of Opn, Sox9 and CK19 by immunohistochemistry. Hepatocytes, bile duct epithelia and proliferative ductular cells are indicated by black, blue and red arrows, respectively

Discussion

Expression of the AP-1 transcription factor c-Jun has been observed in many molecular subtypes of human HCC 20 and is particularly increased in HBV-related HCC.21 c-Jun strongly promotes liver tumorigenesis in mouse models of chemically induced HCC14, 15, 16 and also determines hepatocyte fate in a variety of inflammatory stress conditions including T-cell-mediated hepatitis and ER stress,8, 12 suggesting that c-Jun may also contribute to the pathogenesis of hepatitis-associated HCC. Here, we demonstrate that c-Jun strongly promotes liver tumorigenesis in HBV+ mice, a mouse model that mimics many aspects of the series of pathophysiological events leading to HCC in patients with chronic HBV infection.5, 17 c-Jun regulates hepatocyte survival following DEN-mediated tumor initiation by interfering with c-Fos and Birc515 or with Nos2 and Stat3 signaling in DEN-treated HCV transgenic mice.16 Interestingly, no differences in liver damage could be detected in HBV+ mice lacking c-Jun, in which Birc5 and Stat3 expression were also not altered. In contrast, hepatocyte proliferation was reduced in HBV+ mice lacking c-Jun, indicating that c-Jun rather regulates hepatocyte proliferation in these mice. Increased hepatocyte proliferation may occur in response to HBV-mediated liver damage or through the hepatoviral transactivator HBx or truncated preS2 proteins, all of which are expressed in HBV+ mice and have been shown to promote c-Jun expression.22, 23 Impaired hepatocyte proliferation in the absence of c-Jun correlated with increased expression of the cell cycle inhibitor p21, which is consistent with previous findings in c-Jun–/– mouse embryonic fibroblasts and in c-JunΔli mice following 2/3 partial hepatectomy.13, 24

Expression of the cytokine Opn is an early predictor of HCC formation and predicts its recurrence upon surgical resection, in particular in HBV-infected patients.18, 25 Interestingly, hepatic Opn expression was reduced in the absence of c-Jun in a cell-autonomous manner. Opn is an established AP-1 target gene and its expression is likely regulated by c-Jun and the Fos proteins Fra-1 or Fra-2.26, 27, 28 In HBV+ mice, Opn expression occurred predominantly in bile duct epithelia, proliferating ductular cells and hepatocytes. Recent findings indicate that Opn promotes proliferative ductular reactions following liver damage.29 Interestingly, this ductular reaction and cell numbers expressing the progenitor markers Opn, Sox9 and CK19 were reduced in HBV+ mice lacking c-Jun. These findings suggest that c-Jun may be involved in regulating progenitor cell responses during HBV-related liver damage and hepatocarcinogenesis, which is consistent with the clinical observation that AP-1 expression identifies a subgroup of liver progenitor cell-derived tumors with poor prognosis.30

In conclusion, our findings indicate that c-Jun has important functions during HBV-related hepatocarcinogenesis. Interactions between c-Jun and p21 very likely promote compensatory hepatocyte proliferation, which is a prerequisite for HBV-related hepatocarcinogenesis. Moreover, our findings suggest that c-Jun regulates hepatic Opn expression, thereby contributing to the progression of dysplasia, possibly by interfering with progenitor cell responses. Targeting of c-Jun may therefore be a reasonable approach to interfere with the formation of hepatitis-associated HCC.

Materials and Methods

Mice

Mice with conditional alleles of c-Jun (c-Junf/f) were crossed with transgenic AlfpCre mice to obtain animals with hepatocyte-specific knockout of c-Jun (c-JunΔli).31 These mice were crossed with HBV+ mice (Tg(Alb-1HBV)Bri44).4 Animals were bred on a mixed genetic background (C57BL/6 × 129/Sv × FVB/N) and housed under specific pathogen-free conditions. Either c-Junf/f or AlfpCre c-Junf/f littermates lacking the HBV transgene (HBV-) were used as controls. All animals received humane care and experiments were performed in accordance with local and institutional regulations. In some animals, acute T-cell-mediated hepatitis was induced by injection of ConA (10 mg/kg body weight, Sigma, Taufkirchen, Germany) as previously described.12 Isolation of PMH was performed as described.8 In some experiments, PMH were infected by adenoviral vectors expressing GFP or Cre recombinase (Gene Transfer Vector Core Facility, University of Iowa, Iowa, IA, USA). Briefly, PMH were incubated with adenovirus (10 MOI) for 3 h and collected after 48 h. To study c-Jun expression in a mouse model of HBV infection, C57BL/6 mice were infected with adenovirus (109 U per mouse) encoding an 1.3 HBV overlength genome (AdenoHBV) or empty control virus as described.32 Mice were analyzed 7 days after adenoviral infection.

Cytotoxicity assays and ELISA

Liver damage was determined by analysis of serum ALT using semi-automated clinical routine methods. Opn or LHB concentrations in liver lysates, serum and cell culture supernatants were determined by ELISA according to the manufacturer's protocol (DY441, R&D Systems, Wiesbaden, Germany and EL10018, Abazyme, Needham, MA, USA).

Histology and Immunohistochemistry

For histology, livers were fixed in 3.7% neutral buffered formaldehyde at 4 °C and embedded in paraffin. Immunohistochemistry was performed using the Envision kit (Dako, Hamburg, Germany) and antibodies for c-Jun (#9165; Cell Signaling, NEB, Frankfurt, Germany), Ki67 (#301119; Novocastra, Newcastle, UK), p21 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), Opn (#AF808; R&D Systems), HBsAg (HB100; BioLogo, Kronshagen, Germany), Sox9 (AB5535; Millipore, Schwalbach, Germany), CK19 (TROMA, kindly provided by R. Kemler), CD3 (clone SP7; Thermo Scientific, Fremont, CA, USA) or Ly6G (#551459; BD, Heidelberg, Germany) were used.

qPCR and RNA protection analysis

For isolation of RNA, macrodissected liver tissue was snap-frozen in liquid nitrogen and total RNA was isolated using Qiazol (Qiagen, Hilden, Germany). For isolation of total RNA from PMH, cells were lysed on their culture plate and RNA was extracted using the RNeasy kit (Qiagen). Complementary DNA synthesis was performed using the First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany). qPCR was performed with SYBR Green (Invitrogen, Karlsruhe, Germany) and 10% dimethylsulfoxide (Sigma) on a 480 Lightcycler (Roche, Mannheim, Germany; 40 cycles: 30″ 95 °C; 30″ 60 °C; 40″ 72 °C). Loading was normalized to Hprt and Actin messenger RNA and 18 S ribosomal RNA. All primers were designed using Primer-BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast). Primers were synthesized by Microsynth, Balgach, Switzerland, and the specificity of the PCR products was analyzed by melting curve analysis.

Primer sequences were as follows: Actin: 5′-AGCCATGTACGTAGCCATCC-3′ 5′-CTCTCAGCTGTGGTGGTGAA-3′ 18 S: 5′-CGCGGTTCTATTTTGTTGGT-3′ 5′-AGTCGGCATCGTTTATGGTC-3′ Hprt: 5′-GCTTGCTGGTGAAAAGGACCTC-3′ 5′-CAAATCAAAAGTCTGGGGACGC-3′ c-Jun: 5′-AAAACCTTGAAAGCGCAAAA-3′ 5′-CGCAACCAGTCAAGTTCTCA‘ Opn: 5′-TGCACCCAGATCCTATAGCC-3′ 5′-CTCCATCGTCATCATCATCG-3′ BiP: 5′-AGTGGTGGCCACTAATGGAG-3′ 5′-CAATCCTTGCTTGATGCTGA-3′ Gadd153: 5′-GCATGAAGGAGAAGGAGCAG-3′ 5′-CTTCCGGAGAGACAGACAGG-3′ spliced Xbp-1: 5′-GAGTCCGCAGCAGGTG-3′ 5′-GTGTCAGAGTCCATGGGA-3′ Birc5: 5′-CTCTCCCGGCATGCTCTGCG-3′ 5′-CCGCCATTCGCTCTGGGGTG-3′ p21: 5′-AACTACCAGCTGTGGGGTGA-3′ 5′-GACAACGGCACACTTTGCTC-3′ Sesn2: 5′-TAGCCTGCAGCCTCACCTAT-3′ 5′-GATTTTGAGGTTCCGTTCCA-3′ Ho-1: 5′-CACGCATATACCCGCTACCT-3′ 5′-CCAGAGTGTTCATTCGAGCA-3′ Atf-3: 5′-CTAGAATCCCAGCAGCCAAG-3′ 5′-GGCCAGCTAGGTCATCTGAG-3′ RNase protection analyses were performed using the Riboquant multiprobe RPA system mFos/Jun (BD).

Western blot analysis

Hepatocyte and total liver lysates were analyzed by immunoblot using antibodies for c-Jun (#9165; Cell Signaling), phospho-c-Jun (Ser63, #9261; Cell Signaling), β-Actin (#A2066; Sigma), phospho-Stat3 (Tyr705, #9131; Cell Signaling), Stat3 (#06-596; Millipore), Socs3 (#2932; Cell Signaling), p21 (Santa Cruz), Opn (#AF808; R&D Systems) or LHBs (MA18/07; kindly provided by M Nassal).

Statistics

Data in bar graphs represent mean±S.D. Normal distribution of the data was tested using Graphpad PRISM software (La Jolla, CA, USA). Statistical analysis was performed using the nonparametric Mann–Whitney test or nondirectional two-tailed Student's t-test as indicated in the figure legends.

Acknowledgments

The authors thank M Geissler for providing HBV+ mice, R Kemler and M Nassal for providing antibodies, U Protzer for providing liver samples of adenoHBV-infected mice, O Sansom for help with p21 immunohistochemistry, the animal house staff at the Institute of Molecular Pathology in Vienna, and at Freiburg University Hospital for support, S MacNelly for isolating primary mouse hepatocytes and L Bakiri and R Eferl for helpful comments. This work was supported by the German Research Foundation (DFG, www.dfg.de) grants Ha4314/2-1 and Ha4314/2-2. E.F.W. is supported by a grant from the Spanish Ministry of Economy (BFU2012-40230) and an ERC-Advanced grant (ERC-FCK/2008/37).

Author contributions

EFW, HEB and PH designed the study; CT, BH and PH performed experiments; CT, KZ, RT and PH analyzed the data and PH wrote the paper.

Glossary

HCC

hepatocellular carcinoma

HBV

hepatitis B virus

ER

endoplasmic reticulum

ConA

concanavalin A

ALT

alanine aminotransferase

PMH

primary mouse hepatocytes

AP-1

activator protein 1

The authors declare no conflict of interest.

Footnotes

Supplementary Information accompanies this paper on Cell Death and Differentiation website (http://www.nature.com/cdd)

Edited by T Mak

Supplementary Material

Supplementary Figures
Click here for additional data file. (899.7KB, pdf)
Supplementary Figure Legends
Click here for additional data file. (39.5KB, doc)

References

  1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264–1273.e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23–61. [DOI] [PubMed] [Google Scholar]
  3. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123–135. [DOI] [PubMed] [Google Scholar]
  4. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145–1156. [DOI] [PubMed] [Google Scholar]
  5. Li Y, Tang ZY, Hou JX. Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol 2011; 9: 32–43. [DOI] [PubMed] [Google Scholar]
  6. Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013; 7: 206–223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Toshkov I, Chisari FV, Bannasch P. Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology 1994; 20: 1162–1172. [PubMed] [Google Scholar]
  8. Fuest M, Willim K, Macnelly S, Fellner N, Resch GP, Blum HE et al. The transcription factor c-Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival. Hepatology 2012; 55: 408–418. [DOI] [PubMed] [Google Scholar]
  9. Twu JS, Lai MY, Chen DS, Robinson WS. Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology 1993; 192: 346–350. [DOI] [PubMed] [Google Scholar]
  10. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 1996; 70: 4978–4985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859–868. [DOI] [PubMed] [Google Scholar]
  12. Hasselblatt P, Rath M, Komnenovic V, Zatloukal K, Wagner EF. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc Natl Acad Sci USA 2007; 104: 17105–17110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Stepniak E, Ricci R, Eferl R, Sumara G, Sumara I, Rath M et al. c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev 2006; 20: 2306–2314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003; 112: 181–192. [DOI] [PubMed] [Google Scholar]
  15. Min L, Ji Y, Bakiri L, Qiu Z, Cen J, Chen X et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol 2012; 14: 1203–1211. [DOI] [PubMed] [Google Scholar]
  16. Machida K, Tsukamoto H, Liu JC, Han YP, Govindarajan S, Lai MM et al. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology 2010; 52: 480–492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Huang SN, Chisari FV. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995; 21: 620–626. [PubMed] [Google Scholar]
  18. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55: 483–490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013; 155: 384–396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Malz M, Pinna F, Schirmacher P, Breuhahn K. Transcriptional regulators in hepatocarcinogenesis—key integrators of malignant transformation. J Hepatol 2012; 57: 186–195. [DOI] [PubMed] [Google Scholar]
  21. Guo L, Guo Y, Xiao S, Shi X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci 2005; 77: 1869–1878. [DOI] [PubMed] [Google Scholar]
  22. Tanaka Y, Kanai F, Ichimura T, Tateishi K, Asaoka Y, Guleng B et al. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene 2006; 25: 633–642. [DOI] [PubMed] [Google Scholar]
  23. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 2002; 21: 525–535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 1999; 13: 607–619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC et al. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol 2012; 19(Suppl 3): S455–S463. [DOI] [PubMed] [Google Scholar]
  26. Iqbal J, McRae S, Banaudha K, Mai T, Waris G. Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes. J Biol Chem 2013; 288: 36994–37009. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  27. Hasenfuss SC, Bakiri L, Thomsen MK, Hamacher R, Wagner EF. Activator Protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology 2014; 59: 261–273. [DOI] [PubMed] [Google Scholar]
  28. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci USA 2008; 105: 10525–10530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wang X, Lopategi A, Ge X, Lu Y, Kitamura N, Urtasun R et al. Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 2014; 63: 1805–1818. [DOI] [PubMed] [Google Scholar]
  30. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410–416. [DOI] [PubMed] [Google Scholar]
  31. Behrens A, Sibilia M, David JP, Mohle-Steinlein U, Tronche F, Schutz G et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. Embo J 2002; 21: 1782–1790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Stross L, Gunther J, Gasteiger G, Asen T, Graf S, Aichler M et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology 2012; 56: 873–883. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figures
Click here for additional data file. (899.7KB, pdf)
Supplementary Figure Legends
Click here for additional data file. (39.5KB, doc)

Articles from Cell Death and Differentiation are provided here courtesy of Nature Publishing Group

RESOURCES